Xylocaine 2.0% 400mg/20mL injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

xylocaine 2.0% 400mg/20ml injection ampoule

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Xylocaine 2.0% 100mg/5mL injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

xylocaine 2.0% 100mg/5ml injection ampoule

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Xylocaine 1% (200mg/20mL) injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

xylocaine 1% (200mg/20ml) injection ampoule

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; dilute hydrochloric acid - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Xylocaine 1% (50mg/5mL) ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

xylocaine 1% (50mg/5ml) ampoule

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Marcain 0.5% with adrenaline (epinephrine) 1:200,000 20mL injection vial Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

marcain 0.5% with adrenaline (epinephrine) 1:200,000 20ml injection vial

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml); adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; sodium metabisulfite; water for injections; hydrochloric acid - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia; epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia; continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Marcain 0.5% 100mg/20mL injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

marcain 0.5% 100mg/20ml injection ampoule

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; dilute hydrochloric acid - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

ALDOMET methyldopa (as sesquihydrate) 250 mg tablet bottle Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aldomet methyldopa (as sesquihydrate) 250 mg tablet bottle

aspen pharmacare australia pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: guar gum; titanium dioxide; purified talc; sodium calcium edetate; iron oxide red; citric acid; quinoline yellow aluminium lake; hypromellose; ethylcellulose; propylene glycol; carnauba wax; magnesium stearate; powdered cellulose; colloidal anhydrous silica; citric acid monohydrate - hypertension (mild, moderate to severe).

Panafcortelone 25 mg Tablets bottle Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

panafcortelone 25 mg tablets bottle

aspen pharmacare australia pty ltd - prednisolone, quantity: 25 mg - tablet, uncoated - excipient ingredients: maize starch; crospovidone; magnesium stearate; lactose monohydrate; povidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder

Panafcortelone 5 mg Tablets bottle Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

panafcortelone 5 mg tablets bottle

aspen pharmacare australia pty ltd - prednisolone, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; magnesium stearate; povidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder